360° SearchNetwork Hot Spots Trends Time Series

B-Cell Lymphoma

Type: Keyphrase

Name: B-Cell Lymphoma

First reported 23 hours ago - Updated 23 hours ago - 1 reports

[Comment] Therapy for diffuse large B-cell lymphoma: getting personal

In 1979, Jones and colleagues showed that CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) was superior to CVP (cyclophosphamide, vincristine, and prednisone) in treatment of patients with diffuse lymphomas. This early report probably ... [Published Lancet - 23 hours ago]

Entities: B-Cell Lymphoma, vincristine, cyclophosphamide, prednisone

First reported May 24 2013 - Updated May 24 2013 - 1 reports

University of Alcalá

Studies from University of Alcala Reveal New Findings on Hematology

(NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Hematology. According to news reporting originating from Madrid, Spain, by NewsRx correspondents, research stated, "The activity and safety of two-weekly ... [Published NewsRX - May 24 2013]

Entities: University of Alcalá, Hematology, dexamethasone, B-Cell Lymphoma, Chemotherapy

First reported May 22 2013 - Updated May 22 2013 - 1 reports

An interview with Anthony Calvillo

The Montreal Alouettes’ quarterback talks about fatherhood, football & his futureAnthony Calvillo, his wife, Alexia and their daughters, Olivia and Athena.Photo by Marcie RichstoneMontreal Alouettes' quarterback Anthony Calvillo is one of those rare sports ... [Published Montreal Families - May 22 2013]

Entities: Anthony Calvillo, Cancer, B-Cell Lymphoma, Thyroid

First reported May 21 2013 - Updated May 22 2013 - 1 reports

Seattle Genetics Inc

Seattle Genetics Inc. Presents at UBS Global Healthcare Conference, May-21-2013 11:30 AM

Unknown AnalystGood morning, everyone. Thank you for coming to Day 2 of the UBS Healthcare Conference. My name is David Suki [ph]. I'm with the Healthcare Investment Banking team at UBS here in New York. It's my pleasure to introduce our next speaker, ... [Published Seeking Alpha - May 21 2013]

Entities: Adcetris, Patient, lymphoma, Seattle Genetics Inc, Drugs

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Spectrum Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-20-2013 03:30 PM

Melanie FanHi, good afternoon, everyone. My name is Melanie Fan, I'm happy to be your host for this session. Our next presenter is Raj Shrotriya, the Chairman, President and CEO of Spectrum Pharmaceuticals.We will have a breakout session immediately following ... [Published Seeking Alpha - May 20 2013]

Entities: Drugs, Ibritumomab Tiuxetan, Folotyn

First reported May 19 2013 - Updated May 19 2013 - 1 reports

American Society of Clinical Oncology

Scheduled imaging studies provide little help detecting relapse of aggressive lymphoma

NCI Cancer Center News Imaging scans following treatment for diffuse large B-cell lymphoma do little to help detect a relapse, a Mayo Clinic study has found. The overwhelming majority of patients with this aggressive lymphoma already have symptoms, an ... [Published National Cancer Institute - May 19 2013]

Entities: aggressive lymphoma, Cancer, B-Cell Lymphoma, American Society of Clinical Oncology, Mayo Clinic

First reported May 18 2013 - Updated May 18 2013 - 1 reports

This Week in Blood: May 17, 2013

(WASHINGTON) – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, and Deputy ... [Published American Society of Hematology - May 18 2013]

Entities: prophylaxis, Dendritic Cell, American Society of Hematology

First reported May 16 2013 - Updated May 16 2013 - 5 reports

Mayo Clinic: Scheduled Imaging Studies Provide Little Help Detecting Relapse of Aggressive Lymphoma

ROCHESTER, Minn. -- Imaging scans following treatment for diffuse large B-cell lymphoma do little to help detect a relapse, a Mayo Clinic study has found. The overwhelming majority of patients with this aggressive lymphoma already have symptoms, an abnormal ... [Published ScienceNewsline - May 16 2013]

Entities: aggressive lymphoma, Mayo Clinic, B-Cell Lymphoma, American Society of Clinical Oncology

First reported May 14 2013 - Updated May 14 2013 - 2 reports

Senesco Secures $1.255 Million Equity Financing

Senesco Technologies, Inc. announced that it has entered into a securities purchase agreement with certain institutional investors to raise $1.255 million in gross proceeds through the sale of 41,833,335 shares of its common stock. According to a release, ... [Published Individual.com - May 14 2013]

Entities: Senesco Technologies Inc, Common Shares, B-Cell Lymphoma, Placement Agent

First reported May 13 2013 - Updated May 13 2013 - 4 reports

Lilly's Enzastaurin Phase III study did not meet primary endpoint

5 minutes ago, 12:46pm (ET) 05/13/2013 M2Pharmaceutical products company Eli Lilly and Company (NYSE:LLY) announced on Friday that its Phase III clinical trial results from enzastaurin's PRELUDE study did not meet the primary endpoint.This study explored ... [Published Zecco - May 13 2013]

Entities: primary endpoint, Phase III, Eli Lilly & Company

First reported May 10 2013 - Updated May 11 2013 - 8 reports

Eli Lilly ends development of lymphoma drug

INDIANAPOLIS -- Eli Lilly and Co. said Friday it will stop development of an experimental cancer drug after it failed in a late-stage clinical trial.The company was studying enzastaurin as a treatment for diffuse large B-cell lymphoma, a cancer that affects ... [Published CNBC - May 10 2013]

Entities: Eli Lilly & Company, lymphoma, Drugs

First reported May 01 2013 - Updated May 01 2013 - 2 reports

Oxford BioMedica Announces Lentiviral Vector Collaboration

Oxford BioMedica, the leading gene-based biopharmaceutical company, announces that it has signed an agreement with Novartis to manufacture clinical grade material utilising Oxford BioMedica’s LentiVector® gene delivery technology.Under the terms of the ... [Published PharmaceuticalProcessing - May 01 2013]

Entities: Oxford Biomedica Plc, Vector, collaboration, Novartis AG

Quotes

Earlier this month, Eli Lilly halted development of Phase 3 candidate enzastaurin. The diffuse large B-cell lymphoma [dlbcl] drug "failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of DLBCL relapse following rituximab-based chemotherapy." Although lousy data from enzastaurin is a kick in the pants for Eli Lilly, the company still has a promising oncology pipeline...

Diabetes And Oncology Might Cushion Eli Lilly's Fall Off A Patent Cliff [Published Seeking Alpha - 6 hours ago]

According to the news editors, the research concluded: "Importantly, this improvement in PFS with the two-weekly DA-EDOCH14-R was particularly notable in patients with an age-adjusted International Prognostic Index of 3 (100% vs."

Studies from University of Alcala Reveal New Findings on Hematology [Published NewsRX - May 24 2013]

...chronic lymphocytic leukemia, small lymphocytic lymphoma, and more recently, for Waldenstrm's macroglobulinemia, and mantle cell lymphoma. : "Breakthrough therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. The criteria for breakthrough therapy designation requires preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy. A breakthrough therapy designation conveys all of the fast track program features." The fact that Ibrutinib has obtained breakthrough therapy designation in four different diseases clearly shows the Ibrutinib potential is serious...

Johnson & Johnson's Short-Term Pipeline [Published Seeking Alpha - May 20 2013]

"We worked on a quilt, and we're going to go ahead and have our class picture with all the kids in a square for her," Fulks said. "So we're just trying to keep her in our thoughts and prayers."

Brimfield Elementary students play games and raise money for Team Skylar [Published Record Publishing Online - May 20 2013]

More Content

sort by: Date \| Relevance
Diabetes And Oncology Might Cushion Eli Lilly's... [Published Seeking Alpha - 6 hours ago]
Pfizer Discontinues Late-Stage Trial of Inotuzu... [Published OncLive - 21 hours ago]
[Comment] Therapy for diffuse large B-cell lymp... [Published Lancet - 23 hours ago]
Studies from University of Alcala Reveal New Fi... [Published NewsRX - May 24 2013]
An interview with Anthony Calvillo [Published Montreal Families - May 22 2013]
Mayo Clinic, Cancer Genetics Form Diagnostics V... [Published Genetic Engineering News - May 22 2013]
Cell Therapeutics, Inc. Presents at UBS Global ... [Published Seeking Alpha - May 22 2013]
Seattle Genetics Inc. Presents at UBS Global He... [Published Seeking Alpha - May 21 2013]
Amgen, Inc. Management Presents at UBS Global H... [Published Seeking Alpha - May 21 2013]
Spectrum Pharmaceuticals, Inc. Presents at UBS ... [Published Seeking Alpha - May 20 2013]
Johnson & Johnson's Short-Term Pipeline [Published Seeking Alpha - May 20 2013]
Isis Pharmaceuticals' Management Presents at UB... [Published Seeking Alpha - May 20 2013]
Brimfield Elementary students play games and ra... [Published Record Publishing Online - May 20 2013]
Scheduled imaging studies provide little help d... [Published National Cancer Institute - May 19 2013]
This Week in Blood: May 17, 2013 [Published American Society of Hematology - May 18 2013]
Advisory/UW grads poised for the new economy [Published UW Madison - May 17 2013]
Senesco announces approval to initiate cohort 3... [Published Individual.com - May 17 2013]
Lilly Announces Enzastaurin Phase III Study Did... [Published AAPS Pharmceutica - May 17 2013]
Researchers at Wakayama Medical University Rele... [Published NewsRX - May 17 2013]
Rocheâs obinutuzumab reduces risk of disease pr... [Published PharmaBiz - May 17 2013]
Utility of routine CT scans questioned in B-cel... [Published Oncology Report - May 17 2013]
Mayo Clinic: Scheduled Imaging Studies Provide ... [Published Brightsurf Science News - May 16 2013]
Mayo Clinic: Scheduled Imaging Studies Provide ... [Published ScienceNewsline - May 16 2013]
FDG PET/CT outperforms biopsy for detection of ... [Published MolecularImaging.net - May 16 2013]
Mayo Clinic: Scheduled imaging studies provide ... [Published Bio-Medicine - May 16 2013]
Senesco Technologies Reports Second Quarter Fis... [Published Reuters - May 16 2013]
ASCO: CT unnecessary for lymphoma follow-up? [Published Aunt Minnie - May 16 2013]
ASCO: Studies Highlight Resource Utilization, I... [Published Oncology Business Review - May 16 2013]
Cancer Metabolism as a Therapeutic Target [Published Cancernetwork.com - May 16 2013]
Follow-Up Scans Do Little to Detect Relapse of ... [Published OncLive - May 16 2013]

Blogs

sort by: Date \| Relevance
Eli Lilly enzastaurin Phase III study fails to ... [Published PBR - News - May 13 2013] Eli Lilly and Company's enzastaurin Phase III study has failed to meet primary endpoint in diffuse large B-Cell lymphoma. ...
Fight Aging! Newsletter, February 25th 2013 [Published Fight Aging! - Feb 24 2013] FIGHT AGING! NEWSLETTER February 25th 2013 The Fight Aging! Newsletter is a weekly email containing news, opinions, and happenings for people interested in aging science and engineered longevity: making use of diet, lifestyle choices, technology, and ...
4 Healthcare Stock Stories for Investment Wellness [Published Wall St. Cheat Sheet - Feb 20 2013] Pharmacyclics ( NASDAQ:PCYC ): Current price $88.00 The firm’s shares were downgraded at Leerink Swann from Outperform to Market Perform, but the research firm increased its price target from $80 to $97 on a recent rally. The analyst said, “Following ...
Only Some Mitochondrial DNA Damage Contributes ... [Published Fight Aging! - Feb 20 2013] This research might be taken to illustrate the point that only some specific mutations in mitochondrial DNA (mtDNA) contribute to aging - those occurring in one of thirteen specific genes, per the SENS outline . So mice with accelerated mutation rates ...
Deals Of The Weeks Wonders If A Biopharma Super... [Published The IN VIVO Blog - Feb 01 2013] Deals of the Week is torn as the Super Bowl approaches – you see, most of this feature’s contributors live either in 49ers country near San Francisco or in the case of this author, a short drive from the home field of the Baltimore Ravens. With our ...

Press Releases

sort by: Date \| Relevance
Lilly Announces Enzastaurin Phase III Study Did... [Published PR Newswire: Health - May 10 2013]
Senesco Announces $1.255 Million Equity Financing [Published Business Wire - May 09 2013]
Seattle Genetics Reports First Quarter 2013 Fin... [Published Business Wire - May 07 2013]
Senesco Announces Start of Cohort 3 in Phase 1b... [Published Business Wire Health News - May 06 2013]
Senesco Announces Completion of Cohort 2 of its... [Published Business Wire Health News - Apr 22 2013]